{
  "ticker": "WOA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973119",
  "id": "02973119",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0903",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m66p1c2ys1kj.pdf",
  "summary": "### **Quarterly Activities Report Q2 FY25 (Appendix 4C) Summary**  \n\n#### **Key Highlights:**  \n- **Lupin protein sales**: $233,394 (\u2191226% QoQ), driven by repeat orders from South America, Europe, and Australia.  \n- **China market entry**: Exclusive distribution agreement with Univar Solutions (minimum 50 tonnes over 12 months post 6-month ramp-up).  \n- **Manufacturing efficiency**: Trial achieved **80% energy savings** and **50% faster processing** for core IP step.  \n- **Co-product commercialisation**: Lupin oil (cosmetic applications) advanced\u2014no added capex required.  \n- **German facility expansion**: Capital-efficient pathway to **double capacity** (240 tonnes/year isolate potential).  \n\n#### **Capital Raise & Financials:**  \n- **Placement**: $2.6 million at $0.023/share (closed Q2 FY25).  \n- **SPP**: Additional $182k raised in Q1 FY26.  \n- **Cash balance**: $3.39 million (includes $20k from government grant).  \n- **Net operating cash outflow**: $1.05 million (\u2191production/staff costs).  \n\n#### **Trading Relevance:**  \n- Revenue growth validates product-market fit; scalability improvements support margin expansion.  \n- China distribution deal and Univar partnership materially expand addressable market.  \n\n*No material information omitted; all points derived directly from disclosures.*",
  "usage": {
    "prompt_tokens": 5271,
    "completion_tokens": 304,
    "total_tokens": 5575,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:22:48.801998"
}